← Leaderboards
Gabrielle Lubitz
Icahn School Of Medicine At Mount Sinai
$138,620
Attributed
$138,620
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $47.4K · FY2022–24$50K$37.5K$25K$12.5K$0
'22
'23
'24
Funding mix
By agency
NIH$138,620 · 1
By mechanism
F31$138,620 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Miriam Merad$28,468,631
- Brian D Brown$18,622,393
- Costica Aloman$2,480,715
- Joshua D Brody$3,349,866
- Darrell J Irvine$37,519,809
Others in their field
Other Rising Stars on “Exhibits”
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Jennifer Lee O'Brien · University Of South Florida$10,506,386
- Sophia Zanakos · Icf, Inc., Llc$10,014,539
- David Burkhart · Inimmune Corporation$5,907,864
- Michael Robert Kellen · Northwestern University At Chicago$4,229,149
- Julian A Symons · Hackensack University Medical Center$4,228,031
Research focus
ExhibitsFailureDesignEffective TherapyAntigen-Presenting CellsCytotoxicityAnimal ModelDendritic CellsAdoptive TransferAntigen PresentationAutoantigensAutomobile DrivingAntigensAllogenicAntigen-Specific T CellsCancer TherapyCd8-Positive T-LymphocytesAnti-Pd-1Antitumor EffectChemokineCross PresentationCross-PrimingCxcl9 GeneFlow Cytometry
Grant awards (3)
Defining a cross-primed anti-tumor T cell signature to guide immunotherapy development$47,374
F31 · FY2024 · CA · contact PI
Defining a cross-primed anti-tumor T cell signature to guide immunotherapy development$46,094
F31 · FY2023 · CA · contact PI
Defining a cross-primed anti-tumor T cell signature to guide immunotherapy development$45,152
F31 · FY2022 · CA · contact PI